Short answer
Janux Therapeutics, Inc. (JANX) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 and first-half 2026 financial results announced for periods ended June 30, 2026.
Janux Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 and first-half 2026 financial results announced for periods ended June 30, 2026
- Press release attached as Exhibit 99.1, containing the substantive financial details
- Disclosure furnished under Regulation FD, not filed under Exchange Act Section 18 liability standards
Item EX-99.1 · Exhibit EX-99.1
- Q2 collaboration revenue $10.3M; net loss narrowed to $22.0M from $33.9M year over year
- Cash, equivalents and short-term investments $970.9M, supporting multiple clinical programs
- JANX007 Phase 1b enrollment continues, including taxane-naïve and darolutamide combination cohorts
- JANX013 clinical initiation remains targeted for 2H 2026; JANX011 initial data expected in 2H 2026
- Additional JANX007 clinical data expected at a medical congress in 1H 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Janux Therapeutics, Inc. 8-K filings
Get the next JANX 8-K as it lands
Follow JANX for push alerts, or ask the research agent what this filing means.